source
- Abivax shares jump 40% after Phase 3 data show no excess cancer risk for ulcerative colitis drugAbivax reported new safety data from its Phase 3 trial of obefazimod in ulcerative colitis. The data indicated malignancy rates among trial participants were comparable to background rates observed…
- Ebola and Marburg outbreaks highlight need for pathogen-agnostic diagnosticsThe authors describe a current Bundibugyo Ebola outbreak affecting the Democratic Republic of Congo and Uganda, which has resulted in more than 1,300 confirmed cases and over 375 deaths. While the…